BioPharma Dive December 9, 2024

Sponsored content By Evaluate

There are plenty of questions about what 2025 might hold for the pharmaceutical market. While uncertainty driven by factors like the Inflation Reduction Act (IRA) have been in play for some time, new questions are being raised almost daily with an incoming Trump administration, the BIOSECURE Act, and an ever-changing geopolitical landscape.

However, there are more predictable realities too, including the continued dominance of obesity and other big diseases, and a need for dealmaking driven by the patent cliff which is no longer looming but well and truly upon us.

Pharma is a long game, so what does the picture look like if we cast an eye out to 2030?

The growth boost

The first...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma, Pharma / Biotech
Mark Cuban: A Master Disrupter for American Healthcare
Despite Trump’s Tough Talk On PBMs, GOP House Lets Them Off The Hook
What's next for Amazon in healthcare?
How has U.S. Spending on Health Care Changed Over Time?
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health

Share This Article